BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough to gauge which innovative biotech firms will have something genuinely ground ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Multiple studies had already shown that their benefits might go beyond weight loss and diabetes. Those studies showed that patients taking GLP-1 medication fared better against a wide range of health ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...